Prenetics Global Limited (NASDAQ:PRE – Get Free Report) CFO Brian Rosin acquired 18,000 shares of the stock in a transaction on Monday, August 24th. The stock was bought at an average price of $21.19 per share, with a total value of $381,420.00. Following the transaction, the chief financial officer directly owned 18,000 shares of the company’s stock, valued at approximately $381,420. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Prenetics Global Stock Performance
NASDAQ:PRE opened at $25.76 on Friday. Prenetics Global Limited has a fifty-two week low of $7.41 and a fifty-two week high of $26.50. The firm has a market cap of $434.57 million, a PE ratio of -6.19 and a beta of 0.26. The business has a 50 day moving average price of $19.46 and a 200-day moving average price of $19.08.
Prenetics Global (NASDAQ:PRE – Get Free Report) last issued its earnings results on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.31. The company had revenue of $46.49 million for the quarter, compared to the consensus estimate of $49.85 million. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. Research analysts predict that Prenetics Global Limited will post -1.86 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
PRE has been the subject of a number of analyst reports. B. Riley Financial began coverage on shares of Prenetics Global in a report on Thursday. They set a “buy” rating and a $37.00 target price for the company. Wall Street Zen raised Prenetics Global from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Benchmark increased their price objective on Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $34.80.
Get Our Latest Research Report on PRE
Prenetics Global Company Profile
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
Featured Articles
- Five stocks we like better than Prenetics Global
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
